Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217964 | 1.00 | OPRM1 (0.39) | OPRM1MPOTDP1NPSR1MAPT | |
| SCHEMBL23225713 | 0.93 | OPRM1 (0.39) | OPRM1MPOTDP1NPSR1MAPT | |
| SCHEMBL23225710 | 0.93 | OPRM1 (0.39) | OPRM1MPOTDP1NPSR1MAPT | |
| SCHEMBL23217934 | 0.88 | OPRM1 (0.38) | OPRM1MPOTDP1NPSR1MAPT | |
| SCHEMBL23217932 | 0.88 | OPRM1 (0.38) | OPRM1MPOTDP1NPSR1MAPT | |
| SCHEMBL23225711 | 0.82 | OPRM1 (0.38) | OPRM1MPOTDP1NPSR1MAPT | |
| SCHEMBL23217984 | 0.77 | MPO (0.51) | OPRM1MPONPSR1KMT2AMEN1 | |
| SCHEMBL23225676 | 0.76 | MPO (0.42) | OPRM1MPOMAPTGAAKDM4E | |
| SCHEMBL27102078 | 0.75 | MPO (0.45) | OPRM1MPONPSR1MAPTKMT2A | |
| SCHEMBL27141256 | 0.72 | OPRM1 (0.37) | OPRM1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| WO-2021072140-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | OPRM1 1161/4885MPO 1/4885TDP1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.